Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease

Conditions

Alzheimer´s Disease

What is the purpose of this trial?

This multicenter, randomized, double-blind, placebo-controlled, parallel-group study will evaluate the effect of gantenerumab (RO4909832) on cognition and functioning and the safety and pharmacokinetics in subjects with prodromal Alzheimer's Disease. ; Subject will be randomized to receive subcutaneous injections of either gantenerumab or placebo. ; The anticipated time on study treatment is 104 weeks.


Participation Guidelines

Age:
Gender:

Click here for detailed information about who can participate in this trial.


Sponsor:
Hoffman-La Roche
Roche
Dates:
09/28/2012
Last Updated:
Study HIC#:
1206010395